This study evaluated change in health-related quality of life ( HRQOL ) associated with ongoing weight change among patients with type 2 diabetes mellitus ( T2DM ) treated with dapagliflozin , a highly selective sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor that lowers blood glucose by increasing urinary glucose excretion and is associated with body weight reductions .